<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704063</url>
  </required_header>
  <id_info>
    <org_study_id>T3-NAFL-01-2019</org_study_id>
    <nct_id>NCT04704063</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)</brief_title>
  <acronym>T3-NAFL</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuen Kah Hay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hovid Berhad</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiti Sains Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palm-derived tocotrienols have shown hepatoprotective effects in both animal and human&#xD;
      studies. This study aims to investigate the effects of tocotrienols in hepatocellular lipid&#xD;
      content using MRI. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases&#xD;
      ranging from simple fatty liver (steatosis, NAFL) to non-alcoholic steatohepatitis (NASH) to&#xD;
      cirrhosis. NASH is the accumulation of fat in liver cells accompanied with inflammation that&#xD;
      can lead to the scarring of the liver. Prevention of liver fibrosis by early introduction of&#xD;
      low risk interventions such as lifestyle modification, diet control and nutraceuticals may&#xD;
      help circumvent long-term healthcare costs associated with management of chronic NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Liver Fat (VLFF)</measure>
    <time_frame>12 months</time_frame>
    <description>Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by Magnetic Resonance Imaging - Volumetric Liver Fat Fraction (MRI-VLFF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in liver biochemistry</measure>
    <time_frame>12 months</time_frame>
    <description>Between group difference in mean change of liver biochemistries (ALT, AST, GGT, AP, Bilirubin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver fat fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Between group difference in mean change (%) from Baseline to 12 months in hepatic fat fraction by MRI-VLFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipid profile</measure>
    <time_frame>12 months</time_frame>
    <description>Between group difference in mean change of serum lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events and serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Between group difference in the occurrence of adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Hepatic Steatosis</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocovid Suprabio 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocotrienols / Vitamin E</intervention_name>
    <description>Palm Tocotrienols complex</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Tocovid Suprabio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo matching Tocovid Suprabio</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 70 years old.&#xD;
&#xD;
          2. Diagnosis of non-alcoholic fatty liver (NAFL, hepatic steatosis), using ultrasound or&#xD;
             Fibroscan&#xD;
&#xD;
          3. Willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or evidence of medical condition(s) associated with chronic liver disease&#xD;
             other than NAFL&#xD;
&#xD;
          2. Known history or other evidence of decompensated liver disease (Child-Pugh Grade B or&#xD;
             higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia,&#xD;
             ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions&#xD;
             consistent with decompensated liver disease.&#xD;
&#xD;
          3. Documented underlying medical conditions which may affect assessment or follow-up as&#xD;
             listed:&#xD;
&#xD;
               -  Any malignancies&#xD;
&#xD;
               -  eGFR &lt; 60&#xD;
&#xD;
               -  Severe dementia or psychosis&#xD;
&#xD;
               -  Requirement of long-term corticosteroid treatment for the underlying disease such&#xD;
                  as connective tissue disease&#xD;
&#xD;
               -  Uncontrolled Hemoglobinopathy or anemia&#xD;
&#xD;
               -  Uncontrolled Hyperthyroidism or Hypothyroidism&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Hepatobiliary disorders&#xD;
&#xD;
               -  Participant underwent splenectomy or suffered from splenomegaly&#xD;
&#xD;
               -  Hepatitis B or C&#xD;
&#xD;
          4. History of drug or substance abuse.&#xD;
&#xD;
          5. Estimated alcohol consumption of more than 20 g/day (1 standard drink/day) for women&#xD;
             or more than 30 g/day (2 standard drinks/day) for men for at least 6 months prior to&#xD;
             enrollment, binge drinking behavior or Alcohol Use and Disorders Identification Test&#xD;
             (AUDIT) score of 7 or more&#xD;
&#xD;
          6. History of taking medications known to cause liver impairment such as systemic&#xD;
             glucocorticoids, tetracyclines, anabolic steroids, valproic acid, or other known&#xD;
             hepatotoxins within 3 months prior to study enrollment&#xD;
&#xD;
          7. History of major organ transplantation with an existing functional graft.&#xD;
&#xD;
          8. Present with signs of acute infection or inflammation at Screening&#xD;
&#xD;
          9. Has medical conditions or recent procedures that do not allow for magnetic resonance&#xD;
             (MR) assessments&#xD;
&#xD;
         10. Pregnant, breast feeding, or female of childbearing potential (unless the participant&#xD;
             is on effective contraception methods or underwent bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy previously)&#xD;
&#xD;
         11. Participation in any other interventional trial within the previous three months.&#xD;
             Participants enrolled in this study cannot be enrolled in another study for either&#xD;
             research, diagnostic or treatment purposes.&#xD;
&#xD;
         12. Known history of severe allergy or immunologically mediated disease (e.g., vasculitis,&#xD;
             cryoglobulinemia, inflammatory bowel disease, idiopathic thrombocytopenic purpura,&#xD;
             lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis,&#xD;
             rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory&#xD;
             medications for management, etc.)&#xD;
&#xD;
         13. New treatment with liver-protective supplements such as S-adenosyl methionine (SAM-e),&#xD;
             Ursodeoxycholic acid (UDCA), betain, milk thistle (silymarin), soybean phospholipids&#xD;
             (EssentialE®), or fish oil, within 1 month prior to study enrollment.&#xD;
&#xD;
         14. Treatment with vitamin E tocopherol (at dosage more than 50mg/day) or tocotrienols&#xD;
             within 1 month prior to enrollment.&#xD;
&#xD;
         15. Treatment using new anti-lipidemic or anti-diabetic agents within 3 months prior to&#xD;
             study enrollment.&#xD;
&#xD;
         16. Participant having lesions with a propensity to bleed (e.g., bleeding peptic ulcers)&#xD;
             and those having a history of hemorrhagic stroke and those with inherited bleeding&#xD;
             disorders (e.g., hemophilia) or patients on warfarin.&#xD;
&#xD;
         17. Elevation of AST or ALT greater than five times upper limit normal (ULN),&#xD;
             approximately 250 IU/L, or alkaline phosphatase more than two times ULN (250-300&#xD;
             IU/L).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kah Hay Yuen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universiti Sains Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siok Yee Chan, PhD</last_name>
    <phone>6046532233</phone>
    <email>sychan@usm.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teong Gee Thor, MD</last_name>
    <phone>60355159747</phone>
    <email>thor.teonggee@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KK Bandar Baru Air Itam</name>
      <address>
        <city>Air Itam</city>
        <state>Penang</state>
        <zip>11500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FP Kow, MD</last_name>
    </contact>
    <investigator>
      <last_name>FP Kow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KK Bayan Baru</name>
      <address>
        <city>Bayan Baru</city>
        <state>Penang</state>
        <zip>11950</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siti Khamariah Ahmad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Siti Khamariah Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Seberang Jaya (CRC)</name>
      <address>
        <city>Seberang Jaya</city>
        <state>Penang</state>
        <zip>13700</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Looi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Irene Looi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KK Jalan Perak</name>
      <address>
        <city>Penang</city>
        <zip>11600</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WS Tang, MD</last_name>
    </contact>
    <investigator>
      <last_name>WS Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Sains Malaysia</investigator_affiliation>
    <investigator_full_name>Yuen Kah Hay</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tocotrienols</keyword>
  <keyword>Palm tocotrienol complex</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Hepatic Steatosis</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Fatty Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Tocovid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

